Food and Drug Administration Center for Drug Evaluation and Research

SUMMARY MINUTES OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEETING

September 25, 2003

Provigil®

Holiday Inn Versailles Ballrooms, 8120 Wisconsin Avenue, Bethesda, MD

Members Present (Voting) Claudia H. Kawas, M.D. (Chair)	FDA Participants Robert Temple, M.D.
Jerry S. Wolinsky, M.D.	Russell Katz, M.D.
berry S. Womisky, W.D.	John Feeney, III, M.D.
	Norman Hershkowitz, M.D., Ph.D
	Executive Secretary
	Anuja M. Patel, M.P.H.
Consultants to the PCNS Drugs Advisory Comm Steven Ebert, Pharm. D. (Consumer Representative Gerald van Belle, Ph.D. Jorge C. Kattah, M.D. Emanuel J. Mignot, M.D., Ph.D Lois E. Krahn, M.D. David Neubauer, M.D.	
Daniel Azarnoff, M.D.	
These summary minutes for the September 25, 2003 Drugs Advisory Committee were approved on	3, meeting of the Peripheral and Central Nervous System
I certify that I attended the September 25, 2003, mee Advisory Committee meeting and that these minutes	eting of the Peripheral and Central Nervous System Drugs s accurately reflect what transpired.
//S//	//S//
Anuja M. Patel, M.P.H	Claudia Kawas, M.D.
Executive Secretary	Chair

On September 25, 2003, the Peripheral and Central Nervous System Drugs Advisory Committee met in open session at the Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, Maryland. There were approximately 200 people in attendance.

At 8:00 a.m., the meeting was called to order by Claudia Kawas, M.D., Chair. This was followed by the conflict of interest statement, read by Anuja M. Patel, M.P.H., Executive Secretary, and the introduction of meeting participants.

Open Public Hearing Speaker:

- Richard Gelula, MSW Executive Director, National Sleep Foundation
- Christin Engelhardt Executive Director, American Sleep Apnea Organization

Issue:

Discussion on supplementary new drug application (SNDA 20-717 /S-008) Provigil (modafinil) Tablets, Cephalon, Inc., indicated for use to improve wakefulness in patients with excessive sleepiness associated with disorders of sleep and wakefulness.

FDA Presentation

• Opening Remarks Russell Katz, M.D.

Overview of Issues Director, Division of Neuropharmacologic Drug Products, FDA

Sponsor Presentation

• Introduction Lesley Russell, MBChB, MRCP

Vice President, Clinical Research,

Cephalon Incorporated

• Review of Excessive Sleepiness Thomas Roth, Ph.D.

Division Head, Sleep Disorders and Research Center,

Henry Ford Hospital

Overview of Efficacy
 Rod Hughes, Ph. D

Senior Director, Clinical Research,

Cephalon Incorporated

• Overview of Safety Gwendolyn Niebler, D.O.


Senior Director, Clinical Research,

Cephalon Incorporated

Conclusion
 Lesley Russell, MBChB, MRCP

Vice President, Clinical Research,

Cephalon Incorporated



4. Does the Committee agree that the sponsor has submitted substantial evidence of effectiveness for the indication, "...for the treatment of excessive sleepiness associated with disorders of sleep and wakefulness..."?

Yes - 4 No- 4

Members expressed their reservations such as the global nature of the indication given by the Sponsor. Some felt that it is difficult to highlight these three disorders and say that it is representative of all the disorders.

5. Has the sponsor demonstrated that Provigil can be used safely for this broad indication?

Yes - 5 No- 2 Split-vote- 1

One member of the committee felt that the sponsor demonstrated Provigil can be used safely for the broad indication for narcolepsy and shift work sleep disorders but not for sleep apnea patients. The member suggested that additional information be collected in regards to safety in sleep apnea patients.

If the Committee does not vote "yes" on questions 1-5:

1. Has the Sponsor provided substantial evidence of effectiveness to support the use of Provigil in the treatment of excessive sleepiness in patients diagnosed with OSAHS?

The vote was unanimous; however, some members expressed reservations provided that Provigil be used as adjunctive therapy to C-PAP (Continuous Positive Airway Pressure).

2. Has the Sponsor provided substantial evidence of effectiveness to support the use of Provigil in the treatment of excessive sleepiness in patients diagnosed with SWSD?

Members expressed their opinion that this drug is the treatment of a symptom not on the elimination of a disease and given the fact the drug has a similar effect on that symptom for the other diseases discussed. The committee suggested that strong labeling measures be taken by the Food and Drug Administration to include the sleep apnea and shift work sleep disorders (SWSD).

Committee members that voted "no" were concerned that the criterion is for two independent studies and the Committee was presented one. Furthermore, the conceptual issues of exactly what constitutes the SWSD as oppose to those individuals who are doing shift work and experiencing sleepiness; and also the effectiveness is questionable patients who are still in a range of profound sleepiness.

Following completion of discussion of the questions, the committee adjourned at approximately 2:30 PM.

Prepared by:

Anuja M. Patel, M.P.H. Executive Secretary Peripheral and Central Nervous System Drugs Advisory Committee